Company Overview - The closing price of Aojing Medical (688613.SH) on February 12, 2026, was 23.98 yuan, with a daily decline of 3.54% and a trading volume of 1.10 billion yuan, indicating a turnover rate of 3.31% [1] - As of February 12, the company's price-to-earnings ratio (TTM) was -910.15 times, and the price-to-book ratio was 2.29 times. The revenue forecast for 2025 is 224 million yuan, with a net profit attributable to the parent company of 13.53 million yuan, although the non-recurring net profit is expected to be a loss of 510,000 yuan [3] Industry Analysis - The medical device sector has seen a cumulative decline of 5.39% over the past 20 days, reflecting overall weak performance. Concerns regarding the continuity of medical procurement policies and increased risk aversion ahead of the long holiday have put pressure on small and medium-sized pharmaceutical stocks [4] Market Activity - On February 10, the stock price surged by 5.13% to 25.41 yuan, reaching a new high for the period. The subsequent decline on February 12 is viewed as a technical correction following a significant short-term increase [5] - The financing activity showed a recent trend of increased activity followed by a decline, with a net buy of 9.29 million yuan on February 10, but a net outflow of 7.63 million yuan on February 11, leading to a financing balance of 227 million yuan on February 12. The net outflow of main funds on February 12 indicates a profit-taking pressure from retail investors, who accounted for 38% of the inflow [2]

Core Viewpoint - Recent events surrounding Chengguang Medical primarily focus on shareholder reduction, changes in corporate governance, and financial performance in January 2026 [1] Group 1: Executive Changes - On January 12, 2026, the company announced that shareholder Tian Lifeng reduced her holdings by 156,500 shares from November 13, 2025, to January 9, 2026, decreasing her ownership from 5.7139% to 5.5316% [2] - The combined shareholding with the concerted party Shanghai Fuhun Technology Co., Ltd. fell from 8.1823% to 8.0000%, reaching the threshold for disclosure of equity changes [2] Group 2: Company Status - On January 10, 2026, the board approved a proposal to use idle raised funds for cash management, planning to invest no more than 10 million yuan in low-risk financial products with a maturity of no more than six months to enhance fund utilization efficiency [3] Group 3: Fund Movements - On January 26, 2026, Chengguang Medical recorded a financing buy-in of 357,600 yuan, with a net financing buy-in of 357,600 yuan, bringing the financing balance to 17.3495 million yuan, which accounts for 1.28% of the circulating market value, at a near one-year high level [4] Group 4: Performance and Operating Conditions - On January 29, 2026, the company disclosed its 2025 annual performance forecast, expecting a net loss attributable to shareholders of 53 million to 66 million yuan, compared to a loss of 60.9 million yuan in the same period last year [5] - The performance fluctuation is primarily attributed to intensified competition in the magnetic resonance system industry, with a decline in sales revenue from 1.5T products and no sales achieved for the 7.0T research products [5]

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a slight decline compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, with fluctuations influenced by the weak performance of small-cap stocks[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, highlighting a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating a relatively high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative tier and basic tier seeing transaction amounts drop by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which may lead to further declines in the North 50 Index[42]

Group 1 - The core point of the article is that Chuiyuan Medical Technology (Shanghai) Co., Ltd. has recently completed its Series A financing round, raising 20 million RMB, with the investment coming from Sanyou Medical [1] - Chuiyuan Medical was established in 2021 and is based in Shanghai, focusing on research and experimental development [1] - The company has a registered capital of 5.235102 million RMB and has completed its Series A financing by 2026 [1] Group 2 - The company holds 13 trademark registrations and 11 patents, along with 1 administrative license [1] - The shareholders of Chuiyuan Medical include Shanghai Sailiwei Biotechnology Co., Ltd., Shanghai Qiangji Enterprise Management Partnership (Limited Partnership), Shanghai Kailitai Medical Technology Co., Ltd., Hangzhou Zeyue Zining Venture Capital Partnership (Limited Partnership), and Shanghai Zhangke Hemiao Venture Capital Partnership (Limited Partnership) [1]

Group 1 - The core viewpoint of the news is that Lepu Medical (300003) is expected to see a significant increase in net profit in 2025, driven by a recovery in traditional business and breakthroughs in the medical aesthetics sector [1][2] - The company forecasts a net profit of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95%, ending a previous trend of decline [1] - The medical aesthetics business, particularly the Tongyan needle product, has rapidly gained traction since its launch in August 2025, generating approximately 100 million yuan in revenue by October 2025 [1] Group 2 - The financial report indicates that the growth in net profit is primarily due to the stabilization of traditional business and contributions from emerging sectors, with core cardiovascular intervention revenue showing steady growth [2] - The retail channel inventory for the pharmaceutical segment has been cleared, leading to double-digit growth in formulation revenue, while innovative drugs and medical aesthetics have become new sources of revenue [2] - The company expects a nearly 95% increase in net cash flow from operating activities, with a stable debt-to-asset ratio of 31%, indicating a solid financial position [2] Group 3 - Recently, Lepu Medical's stock price has shown limited volatility, closing at 17.98 yuan on February 11, 2026, with a slight decline of 0.17% on that day [3] - Over a 5-day period, the stock has seen a minor increase of 0.11%, but a notable decline of 11.38% over 20 days indicates short-term fluctuations [3] - The stock is positioned near the lower band of the Bollinger Bands, with weak MACD indicators, although the 60-day moving average provides support [3]

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a decline in trading activity compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, reflecting significant volatility in the market[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, indicating a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative layer and basic layer trading amounts dropping by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which could lead to further declines in the North 50 Index[42]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. is the first innovative medical device company to be accepted for IPO under the fifth set of listing standards of the Sci-Tech Innovation Board, aiming to raise 1.217 billion yuan for various projects, including R&D and marketing network development [1][6] Group 1: Company Overview - Core Medical is a leader in China's artificial heart industry, holding multiple "first" titles [4] - The company has several products included in China's special review process for innovative medical devices, leading the field in terms of the number of products [5] - The Corheart 6, the world's smallest and lightest commercialized magnetic levitation implantable artificial heart, was approved for market in June 2023, with a projected market share of over 45% in 2024 [5] Group 2: Financial Performance - The company reported revenues of 16.55 million yuan, 93.69 million yuan, and 70.48 million yuan for the years 2023, 2024, and the first half of 2025, respectively, with net losses of 170 million yuan, 132 million yuan, and 72.75 million yuan during the same periods [8] - Cumulative losses since 2022 have exceeded 500 million yuan [8] - Gross margins for the reporting periods were 66.25%, 69.66%, and 72.09%, consistent with industry averages [9] Group 3: Investment and Financing - Prior to the IPO, Core Medical attracted investments from several prominent institutions, including Hillhouse Capital and Zhengxin Valley Investment [2][14] - The company completed a D-round financing of over 100 million USD in April 2025, marking the largest market-based financing in China's innovative medical device sector for that year [16]

Core Viewpoint - The article emphasizes the importance of ensuring the safety of pharmaceuticals and medical devices during the winter season through a regulatory initiative in Xinjiang Shawan City, aimed at protecting public health [1] Group 1: Regulatory Actions - The Xinjiang Shawan City Market Supervision Administration is conducting a "100-day rectification action" focused on the quality and safety of pharmaceuticals and medical devices during winter [1] - The initiative targets pharmaceutical and medical device businesses, verifying the validity of operating licenses, legality of procurement channels, compliance in storage and maintenance, and completeness of incoming inspection [1] Group 2: Focus Areas - Key areas of focus include cold-chain pharmaceuticals, traditional Chinese medicine pieces, and commonly used medical devices [1] - The enforcement personnel are combining law enforcement with service, providing on-site guidance for businesses to standardize management and assisting with license changes [1] Group 3: Future Plans - The Xinjiang Shawan City Market Supervision Administration plans to continue enhancing precise regulation and warm service to further advance the "100-day rectification action" for pharmaceutical and medical device quality and safety [1] - The initiative aims to reinforce the primary responsibility of enterprises, ensuring that the public can use medications and medical devices with greater confidence during the winter [1]

Core Viewpoint - Anxu Bio (688075) has disclosed its 2025 performance forecast, expecting a significant decline in net profit and a delay in its fundraising project until 2027 [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan, representing a year-on-year decrease of 55.80% to 63.08% [2] - The expected non-recurring net profit is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [2] - The performance decline is primarily attributed to increased tariffs in the U.S. leading to reduced orders, foreign exchange losses due to currency fluctuations, decreased interest income, and asset depreciation [2] Project Progress - The company announced on January 30, 2026, that the completion date for its "in vitro diagnostic reagents and diagnostic instruments R&D and production project" has been postponed from January 2026 to January 2027 [3] - The delay is attributed to the impact of global respiratory infectious diseases on renovation progress and delays in equipment investment [3] Company Status - Shareholder Ma Huaxiang reduced his stake in the company by selling 804,500 shares between January 6 and January 21, 2026, decreasing his holding from 11.62% to 10.99%, which has reached the 1% threshold for equity change [4] Business and Technical Development - The company is actively transitioning from a single product focus to a comprehensive health management approach, including the expansion of pet testing products and chronic disease management apps [5] - The company is deepening its overseas market presence, with multiple international certifications expected in 2025, although related investments may lead to increased short-term expenses [5]

Group 1 - The Hong Kong innovative drug concept stocks have declined, with companies such as 3SBio, Kelun-Botai Biopharmaceuticals falling over 3%, and CSPC Pharmaceutical Group, China Biologic Products, and Hansoh Pharmaceutical dropping over 2% [1] - The Hong Kong innovative drug-related ETFs have also seen a decline of over 2% [1] Group 2 - Current analysis indicates that the healthcare sector presents multiple investment opportunities, with the CXO industry experiencing sustained improvement due to a recovery in overseas orders and domestic capacity reduction, while still having room for valuation recovery [2] - The medical device sector is benefiting from domestic equipment upgrade policies and overseas market expansion, with continuous catalysts in cutting-edge areas such as brain-computer interfaces and AI imaging [2] - Internet healthcare is seeing improved operational efficiency in the context of deepening medical insurance payment reforms, leading to a clearer profit growth trajectory [2]